A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

What is the purpose of this trial?

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.


Participation Guidelines

Ages: 18 years and younger

Gender: Both


Hoffman-La Roche

Start Date: 03/05/2018

End Date: 12/31/2018

Last Updated: 03/07/2018

Study HIC#: 2000020755